在生物类似时代,扩散性大B细胞淋巴瘤的现实结果
Reena Nair1, Gull Mohammad Bhat2, Narendra Agrawal3
1Department of Clinical Haematology, Tata Medical Centre, Kolkata, West Bengal, India.
Frontiers in oncology
|October 19, 2023
概括
两种rituximab生物仿制疗法RedituxTM和Ristova®在扩散性大B细胞淋巴瘤 (DLBCL) 患者中表现出可比的现实有效性和安全性. 这项研究支持它们作为B细胞淋巴细胞恶性瘤的经济有效选择.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是非霍奇金淋巴瘤 (NHL) 的最常见和最激进的形式.
- 利图西马布显著改善了DLBCL患者的治疗结果和生存率.
- 利图西马布生物仿制剂的引入提供了一个具有成本效益的替代品,提高全球患者获得B细胞淋巴细胞恶性瘤的标准护理的机会.
研究的目的:
- 评估RedituxTM和Ristova®在被诊断为DLBCL的患者中的实际有效性和安全性.
- 在一大群患者中,比较两种rituximab生物相似治疗的临床结果和安全概况.
主要方法:
- 从2015年到2022年,在29个印度中心进行了观察性研究.
- 包括接受RedituxTM或Ristova®的DLBCL成年患者.
- 有效性和安全性结果在初始剂量后长达两年的时间内进行评估.
主要成果:
- 分析包括1365名患者;91.6%接受RedituxTM,8.42%接受Ristova®.
- 两年后,无进展生存率 (PFS) 为69%,总生存率 (OS) 为78.7%,两个生物相似组的结果相似.
- 六个月的最佳整体响应率 (BORR) 也相似 (89.2% vs 94.3%),没有统计学上显著的差异.
结论:
- 在DLBCL的实际治疗中,RedituxTM和Ristova®的有效性和安全性表现相似.
- 这些发现支持使用rituximab生物相似的选择作为DLBCL患者的有效治疗选择.
相关概念视频
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
133
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
133
Biopharmaceutics and Pharmacokinetics: Overview
2.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.1K
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)